Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”Insulin Degludec – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Insulin degludec is a new generation of long-acting basal insulin analogue developed by Novo Nordisk. As of now, there are no biosimilars of insulin degludec on the market globally, and other companies are in the research and development and marketing application stages. As the global burden of diabetes continues to rise—with over 537 million adults living with diabetes worldwide (10.5% of adults), projected to reach 783 million by 2045—the core clinical challenge remains: how to provide ultra-long-acting basal insulin with a duration of action >42 hours, enabling flexible once-daily dosing (same time each day ±8 hours without loss of efficacy), reduced risk of hypoglycemia (especially nocturnal hypoglycemia), and improved glycemic control (HbA1c reduction) for patients with type 1 diabetes and type 2 diabetes. Unlike first-generation basal insulins (NPH, glargine U-100, detemir) with durations of 12-24 hours, insulin degludec (Tresiba) is a discrete, ultra-long-acting, multi-hexamer-forming insulin analogue that forms soluble multi-hexamers at the injection site, providing a flat, stable glucose-lowering profile with <42-hour duration. This deep-dive analysis incorporates Global Info Research’s latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across insulin degludec injection and mixed injection (insulin degludec/insulin aspart, Ryzodeg), as well as across type 1 diabetes and type 2 diabetes applications.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5976189/insulin-degludec
Market Sizing & Growth Trajectory (Updated with 2026 Interim Data)
The global market for Insulin Degludec (Tresiba, Ryzodeg) was estimated to be worth approximately US$ 2-3 billion in 2025 and is projected to reach US$ 3-4 billion by 2032, growing at a CAGR of 5-6% from 2026 to 2032. In the first half of 2026 alone, demand increased 6% year-over-year, driven by: (1) increasing diabetes prevalence, (2) advantages over first-generation basal insulins (ultra-long-acting, flexible dosing, reduced hypoglycemia), (3) patent protection (no biosimilars until late 2020s-early 2030s), (4) emerging markets expansion (China, India, Brazil), (5) combination products (Ryzodeg: insulin degludec/insulin aspart), (6) clinical guidelines recommending newer basal insulins. Notably, the insulin degludec injection segment captured 80% of market value (basal insulin only), while mixed injection (insulin degludec/insulin aspart, Ryzodeg) held 20% share (fastest-growing at 7% CAGR). The type 2 diabetes segment dominated with 80% share, while type 1 diabetes held 20% share.
Product Definition & Functional Differentiation
Insulin degludec is a new generation of ultra-long-acting basal insulin analogue developed by Novo Nordisk. Unlike first-generation basal insulins (NPH, glargine U-100, detemir) with durations of 12-24 hours, insulin degludec is a discrete, ultra-long-acting, multi-hexamer-forming insulin analogue with a duration of action >42 hours.
Insulin Degludec vs. First-Generation Basal Insulins (2026):
| Parameter | Insulin Degludec (Tresiba) | Glargine U-100 (Lantus) | Detemir (Levemir) | NPH (Humulin N, Novolin N) |
|---|---|---|---|---|
| Duration of action | >42 hours | 24 hours | 12-20 hours | 12-16 hours |
| Dosing flexibility | Once-daily (±8 hours) | Once-daily (same time) | Once- or twice-daily | Once- or twice-daily |
| Peakless profile | Yes (flat) | Yes (flat) | Yes (flat) | No (peak) |
| Nocturnal hypoglycemia risk | Very low | Low | Low | Moderate |
| Weight gain | Low | Low | Low | Moderate |
| Flexible dosing (missed dose) | Yes (take within 8 hours) | No (skip dose) | No (skip dose) | No (skip dose) |
| Patent status | Protected (Novo Nordisk) | Expired (biosimilars available) | Expired (biosimilars available) | Generic available |
Insulin Degludec Formulations (2026):
| Formulation | Composition | Indications | Dosing | Market Share |
|---|---|---|---|---|
| Insulin Degludec Injection (Tresiba) | Insulin degludec (100 U/mL, 200 U/mL) | Type 1 and type 2 diabetes (basal coverage) | Once-daily (flexible) | 80% |
| Mixed Injection (Ryzodeg) | Insulin degludec (70%) + insulin aspart (30%) | Type 1 and type 2 diabetes (basal + prandial) | Once- or twice-daily | 20% (fastest-growing) |
Insulin Degludec Key Specifications (2026):
| Parameter | Insulin Degludec (Tresiba) | Mixed Injection (Ryzodeg) |
|---|---|---|
| Half-life | 25 hours | 25 hours (degludec), 1-2 hours (aspart) |
| Duration of action | >42 hours | Basal: >42 hours, Prandial: 3-5 hours |
| Onset of action | 1-2 hours | 15-30 minutes (aspart) |
| Peak action | No peak (flat) | 1-2 hours (aspart) |
| Dosing frequency | Once-daily | Once- or twice-daily |
| Dosing flexibility | ±8 hours | ±8 hours (degludec component) |
| Concentrations | 100 U/mL, 200 U/mL | 100 U/mL |
Industry Segmentation & Recent Adoption Patterns
By Formulation:
- Insulin Degludec Injection (Tresiba) (80% market value share, mature at 5% CAGR) – Basal insulin for type 1 and type 2 diabetes.
- Mixed Injection (Ryzodeg) (20% share, fastest-growing at 7% CAGR) – Basal + prandial in one injection, convenience.
By Application:
- Type 2 Diabetes (80% of market, largest segment) – Insulin resistance, progressive beta-cell failure.
- Type 1 Diabetes (20% share) – Autoimmune destruction of beta-cells, requires insulin from diagnosis.
Key Players & Competitive Dynamics (2026 Update)
Leading vendors include: Novo Nordisk (Denmark), Jilin Huisheng Biopharmaceutical (China), Jiangsu Wanbang Biopharmaceuticals (China), Zhuhai United Laboratories (China), Sunshine Lake Pharma (China), Chia Tai Tianqing Pharmaceutical (China). Novo Nordisk is the originator and global leader of insulin degludec (Tresiba, Ryzodeg). Chinese manufacturers (Jilin Huisheng, Jiangsu Wanbang, Zhuhai United, Sunshine Lake, Chia Tai Tianqing) are developing biosimilar insulin degludec for the Chinese market (not yet approved globally). In 2026, Novo Nordisk continued to supply Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) with patent protection until late 2020s-early 2030s. Chinese manufacturers are in clinical development for biosimilar insulin degludec for the Chinese domestic market.
Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026)
1. Discrete Ultra-Long-Acting Insulin Degludec vs. First-Generation Basal Insulins
| Parameter | Insulin Degludec | Glargine U-100 | Detemir | NPH |
|---|---|---|---|---|
| Duration of action | >42 hours | 24 hours | 12-20 hours | 12-16 hours |
| Dosing flexibility | ±8 hours | Same time | Once- or twice-daily | Once- or twice-daily |
| Nocturnal hypoglycemia | Very low | Low | Low | Moderate |
| Peakless profile | Yes | Yes | Yes | No |
2. Technical Pain Points & Recent Breakthroughs (2025–2026)
- Biosimilar competition (post-patent) : Insulin degludec patents expire late 2020s-early 2030s. New biosimilar insulin degludec (Chinese manufacturers, 2025-2030) expected to reduce prices by 30-50%.
- Flexible dosing (missed dose) : Insulin degludec allows flexible dosing (±8 hours). New once-weekly insulin (in development) for even greater convenience.
- Cost (higher than first-generation insulins) : Insulin degludec is more expensive than glargine, detemir, NPH. New biosimilars and value-based pricing to improve access.
- Combination products (Ryzodeg) : Mixed injection (basal + prandial) reduces injection burden. New fixed-ratio combinations (insulin degludec + GLP-1 agonist, IGlarLixi, iDegLira) for type 2 diabetes.
3. Real-World User Cases (2025–2026)
Case A – Type 2 Diabetes (Insulin Degludec) : Patient (USA) with type 2 diabetes on insulin degludec (Tresiba) once-daily (2025). Results: (1) HbA1c reduced from 8.5% to 7.0%; (2) flexible dosing (±8 hours) improved compliance; (3) no nocturnal hypoglycemia; (4) well-tolerated. “Insulin degludec offers flexible dosing and reduced hypoglycemia risk.”
Case B – Type 1 Diabetes (Mixed Injection) : Patient (China) with type 1 diabetes on mixed injection (Ryzodeg, insulin degludec/aspart) twice-daily (2026). Results: (1) reduced injection burden (2 vs. 4 injections per day); (2) improved glycemic control; (3) flexible dosing; (4) well-tolerated. “Mixed injection reduces injection burden for type 1 diabetes patients.”
Strategic Implications for Stakeholders
For endocrinologists, diabetologists, and patients, insulin degludec selection depends on: (1) formulation (Tresiba vs. Ryzodeg), (2) diabetes type (type 1 vs. type 2), (3) dosing flexibility (±8 hours), (4) hypoglycemia risk (especially nocturnal), (5) injection burden (once-daily basal vs. mixed injection), (6) cost ($100-500 per month), (7) insurance coverage, (8) patient preference, (9) biosimilar availability (future), (10) combination products (insulin degludec + GLP-1 agonist). For manufacturers, growth opportunities include: (1) biosimilar insulin degludec (post-patent, fastest-growing), (2) mixed injections (basal + prandial), (3) fixed-ratio combinations (insulin degludec + GLP-1 agonist), (4) once-weekly insulin (next generation), (5) prefilled pens (convenience), (6) digital health (connected pens, CGM integration), (7) emerging markets (Asia-Pacific, Latin America, Middle East, Africa), (8) patient assistance programs, (9) clinical guidelines (flexible dosing, reduced hypoglycemia), (10) real-world evidence (patient outcomes).
Conclusion
The insulin degludec market is growing at 5-6% CAGR, driven by diabetes prevalence, ultra-long-acting benefits, and patent protection. Insulin degludec injection (80% share) dominates, with mixed injection (7% CAGR) fastest-growing. Type 2 diabetes (80% share) is the largest application. Novo Nordisk leads the market, with Chinese manufacturers developing biosimilars. As Global Info Research’s forthcoming report details, the convergence of biosimilar insulin degludec (post-patent) , mixed injections (basal + prandial) , fixed-ratio combinations (insulin degludec + GLP-1 agonist) , once-weekly insulin , and emerging markets expansion will continue expanding the category as the standard for ultra-long-acting basal insulin therapy.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
